Cefoxitin And Dextrose In Duplex Container

(Cefoxitin)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cefoxitin And Dextrose In Duplex Container is one of 110 small molecule programs targeting Pyelonephritis. It is currently in Approved.

Indications

Total Trials

Active Trials

109

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PyelonephritisActive, not recruiting

AppendicitisActive, not recruiting

Cystic FibrosisNot yet recruiting

AbscessRecruiting

Urinary Tract InfectionTerminated

PyelonephritisPreclinical

Active, not recruiting

AppendicitisPhase 1

Active, not recruiting

Cystic FibrosisPhase 2

Not yet recruiting

AbscessPhase 3

Recruiting

Urinary Tract InfectionApproved

Terminated

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Cefoxitin And Dextrose In Duplex Container

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 2

Ibsrela

AArdelyx

Phase 3

1 3

Biaxin

AbbVie

Phase 2

2 4

Lamprene

Novartis

Phase 2

1 5

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

2 6

Sirturo

WWim Janssens

Phase 2

1 7

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

18 8

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

4 9

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

1 10

VX-121/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Appendicitis

NCT06860802

Q2 2030

Phase 2/3Recruiting

Abscess

NCT04310930

Q3 2031

Phase 2Not yet recruiting

Cystic Fibrosis

NCT07485010

Clinical

Trials by Indication[1]

Antibiotic Prophylaxis1 trial

Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

Unknown status·HHospital de Santa Maria, Portugal·N/A·NCT02985086·568 enrolled

Cystic Fibrosis1 trial

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruiting·TThe University of Queensland·Phase 2·NCT07485010·300 enrolled

Urinary Tract Infection1 trial

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Terminated·—·Phase 4·NCT02474706·6 enrolled

Major Abdominal Surgery1 trial

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

Completed·PPoitiers University Hospital·Phase 4·NCT02703857·12 enrolled

Abscess1 trial

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting·TThe University of Queensland·Phase 2/3·NCT04310930·300 enrolled

3 more indications

Surgical Site Infections1 trial

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03269994·967 enrolled

Pyelonephritis1 trial

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Terminated·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01820793·9 enrolled

Appendicitis1 trial

Aim 3 - Precision Coordination of Therapeutic and Prophylactic Antibiotics to Reduce Infection, Toxicity, and Emergence of Resistance Following Acute Abdominal Surgery

Active, not recruiting·UUniversity of Michigan·Phase 1·NCT06860802·46 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MEFOXIN

NDA NDA050517

Sep 20, 1984

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA050581

Mar 10, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

NDA NDA065214

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cefoxitin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cefoxitin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cefoxitin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA065214). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cefoxitin And Dextrose In Duplex Container

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2030

Q3 2031

Trials by Indication[1]

Antibiotic Prophylaxis1 trial

Cystic Fibrosis1 trial

Urinary Tract Infection1 trial

Major Abdominal Surgery1 trial

Abscess1 trial

Surgical Site Infections1 trial

Pyelonephritis1 trial

Appendicitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News